Souhaitez-vous accéder aux communiqués récents ?

ORLANDO, Fla, Dec. 07, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the presentation of pre-clinical data describing the synergy of the Company’s next generation...

Single agent TGR-1202 continues to demonstrate a favorable safety profile, differentiated from other PI3K delta inhibitors, with only 7% of patients discontinuing due to an adverse eventCollectively,...

Combination of TG-1101 plus TGR-1202 (“TG-1303”) continues to demonstrate a favorable safety profile, with only 8% of patients discontinuing due to an adverse event and no cases of colitis reported...

ORLANDO, Fla., Dec. 04, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today recapped the schedule of data presentations for their lead compounds at the upcoming 57th American...

NEW YORK, Nov. 09, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the third quarter ended September 30, 2015 and recent company...

Company to Host Third Quarter Earnings Conference Call to Review Financial Results, Business Updates as well as Provide an Overview of the ASH Abstract Data, on Monday November 9, 2015 at 8:30 am ET...

NEW YORK, Nov. 04, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Monday, November 9, 2015 at 8:30am ET to discuss results for...

NEW YORK, Sept. 25, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will...

Novel Design Allows for Simultaneous Approval of Two Investigational Agents in a Single Phase 3 Study Under SPA Study Will Include Both Front-Line and Previously Treated Patients With CLL...

NEW YORK, Sept. 9, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the initiation of a Phase 1/2 clinical study that will investigate the use of TGR-1202, the Company's...